Methsuximide

Summary

Methsuximide (CHEMBL697) is an approved small molecule (ATC N03AD03); indicated across 2 conditions including epilepsy and visual epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AD03
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 203.24 Da · C12H13NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL697
Name	Methsuximide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6476
ATC	N03AD03
Molecular formula	C12H13NO2
Molecular weight	203.24
InChIKey	AJXPJJZHWIXJCJ-UHFFFAOYSA-N

SMILES: CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2

IUPAC name: 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione

Also known as: Celontin, Mesuximida, Mesuximide, Methsuximide, NSC-760075, METHSUXIMIDE, methsuximide, SID144207162, MethsuximideÊ, MethsuximideÂ, MESUXIMIDE

Patent coverage: 1,542 distinct patent families (6,189 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474
visual epilepsy	4	MONDO:0001386	HP:0001250

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03196466	Not specified	COMPLETED	Population Pharmacokinetics of Antiepileptic in Pediatrics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).